Seladelpar

The approval of Lynavoy comes a few days ahead of the FDA's March 24 decision target date. Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. After inking a deal worth up to $690 million to take on worldwide rights to the med last week, the FDA has doled out an approval a few days ahead of schedule.The drug, approved under the moniker Lynavoy, is an ileal bile acid transporter inhibitor that was designed to reduce multiple drivers of chronic itch. With the approval, the med is in position to reach the 89% of people with primary biliary cholangitis (PBC) who experience cholestatic pruritus, an often debilitating itching condition. The FDA signed off on the med a few days ahead of its March 24 decision target date based on GSK’s phase 3 Glisten trial, which showed Lynavoy significantly improved itch symptoms versus placebo over 24 weeks. Despite handing Lynavoy off to Alfasigma on March 9, the nod is still a milestone moment for GSK, as it represents “the first liver medicine from our pipeline to receive approval,” Kaivan Khavandi, M.D., Ph.D., GSK’s head of R&D for respiratory, immunology and inflammation, said in a company release.While “proud of the role” GSK played in discovering and developing the drug, the British pharma giant ultimately landed on Alfasigma as “the right partner to take this medicine forward” based on the Italian pharma’s experience in the PBC space, GSK’s chief scientific officer Tony Wood, Ph.D., explained at the time. Through the deal, GSK earned an upfront payment of $300 million plus an extra $100 million upon the FDA approval. The company is also in line for $20 million related to overseas regulatory approvals, plus up to $270 million in sales-based milestone payments and tiered double-digit royalties on net sales worldwide. The transaction has not yet closed, and Alfasigma is still “working closely with GSK,” it said in its own Thursday release. Alfasigma considers itself “uniquely positioned” to lead the worldwide commercialization of Lynavoy, given its “deep hepatology expertise and strong global footprint,” CEO Francesco Balestrieri said of the deal.  The company’s PBC experience stems from its 2023 $800 million buyout of Intercept Pharmaceuticals, which was inked after years of struggles for Intercept and its PBC med Ocaliva. After winning an accelerated approval for the treatment in 2016, Intercept’s attempts to grow the med with a full approval and with an expansion into metabolic dysfunction-associated steatohepatitis were both shot down multiple times. The drug fully sputtered out last year, when Intercept acquiesced to the FDA’s requests to withdraw Ocaliva from the market following continued safety concerns.Some six months later, Aflasigma will make its comeback in the PBC space through Lynavoy. With Ocaliva out of the race, the drug enters a market populated by Ipsen’s Iqirvo and Gilead Sciences’ Livdelzi, both of which hit the market in 2024.  Both companies have been recently reaping the benefits of the extra room in the PBC space, with Gilead reporting higher demand due to the Ocaliva withdraw and Ipsen touting growing momentum based on Ocaliva patient switches. Iqirvo garnered 77 million euros ($88.6 million) during the fourth quarter of 2025, while Livdelzi picked up $150 million.Lynavoy, meanwhile, is poised to corner a different core group of PBC patients with its cholestatic-pruritus-specific label. The condition can occur at any stage of the liver disease and has been “underestimated and overlooked for far too long, despite its significant impact on people living with PBC,” president of the PBCers Organization, Carol Roberts, noted in GSK’s release. 

Issued on behalf of Oncolytics Biotech Inc. 代表Oncolytics Biotech Inc.发布。VANCOUVER, BC 加拿大温哥华 , ，March 19, 2026 2026年3月19日/PRNewswire/ -- /PRNewswire/ --USANewsGroup.com 美国新闻组.comNews Commentary 新闻评论— The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035 ——2026年全球肿瘤学市场估值为2799.8亿美元，预计到2035年将达到7481.7亿美元。[1] [1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032 ，这一结构性调整是由从单一药物治疗向协同组合平台和下一代细胞疗法转变所驱动的。仅免疫肿瘤领域预计就将从2025年的652.2亿美元增长到2032年的1701.9亿美元。[2] [2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like ，随着一波联合疗法的批准，曾经对免疫疗法产生耐药性的肿瘤转化为可行的治疗目标。各机构正在通过像这样的公司为这一转变做好准备。Oncolytics Biotech Oncolytics生物技术公司(NASDAQ: （纳斯达克：ONCY ONCY), ), Gilead Sciences 吉利德科学公司(NASDAQ: （纳斯达克：GILD 吉利德科学公司), ), enGene Holdings 恩基控股(NASDAQ: （纳斯达克：ENGN 工程学), ), TScan Therapeutics TScan治疗公司(NASDAQ: （纳斯达克：TCRX TCRX), and ），以及Day One Biopharmaceuticals 第一天生物制药公司(NASDAQ: （纳斯达克：DAWN 黎明) (soon to be ）（很快就会Servier 施维雅), which are each advancing translational data or near-term regulatory milestones in the 2026 cycle. ），这些公司在2026周期中各自推动转化数据或近期监管里程碑的发展。Goldman Sachs 高盛集团has projected 2026 will be a record-breaking year for biopharma dealmaking, with pharma and biotech companies remaining the primary target as a patent cliff looms which could result in the loss of hundreds of billions in revenue 预计2026年将成为生物制药交易破纪录的一年，由于专利悬崖的临近，制药和生物技术公司仍然是主要目标，这可能导致数千亿美元的收入损失。[3] [3]. This structural shift creates a window for companies with asymmetric upside in high-value solid tumor markets, as the 这种结构性转变为企业在高价值实体瘤市场中创造了具有不对称上升潜力的窗口，因为FDA's 美国食品药品监督管理局的expanded accelerated approval framework—now covering gene therapies and next-generation combination regimens—compresses the timeline from translational data to commercial launch, making regulatory milestones the primary value driver for the 2026 immuno-oncology investment cycle 扩大加速审批框架——现涵盖基因疗法和下一代联合治疗方案——压缩了从转化数据到商业上市的时间表，使得监管里程碑成为2026年免疫肿瘤投资周期的主要价值驱动力。[4] [4]. 。Oncolytics Biotech Oncolytics生物技术公司(NASDAQ: （纳斯达克：ONCY ONCY) is presenting new ）正在展示新的mechanistic and translational data 机制和转化数据at the 在American Association for Cancer Research (AACR) 美国癌症研究协会 (AACR)Annual Meeting in San Diego this April, data that adds scientific depth to the company's push into some of cancer's hardest-to-treat corners. 今年四月在圣地亚哥举行的年度会议上，增添了公司深入癌症最难治疗领域的科学深度的数据。The two abstracts, drawn from the AWARE-1 breast cancer study and the GOBLET gastrointestinal cancer trial, both center on the same question: can pelareorep, the company's lead drug, make tumors more vulnerable to immunotherapy? The short answer, based on these findings, appears to be yes. In AWARE-1, biopsies showed pelareorep triggering the formation of tertiary lymphoid structures, essentially localized immune hubs that help the body mount a sustained attack on cancer cells.. 这两个摘要来自 AWARE-1 乳腺癌研究和 GOBLET 胃肠癌试验，都围绕同一个问题：公司主导药物 pelareorep 是否能使肿瘤更容易受到免疫疗法的影响？根据这些发现，简短的回答似乎是肯定的。在 AWARE-1 中，活检显示 pelareorep 会触发三级淋巴结构的形成，本质上是局部的免疫中心，帮助身体对癌细胞发起持续攻击。Tumors that would otherwise stay 'cold' and invisible to the immune system showed signs of becoming 'hot.' In GOBLET Cohort 1, patients with pancreatic cancer who showed early immune activation after four weeks on a pelareorep-based regimen lived longer without their disease progressing than those who did not, 7.5 months compared to 5.6 months. 否则会保持“冷”状态并对免疫系统不可见的肿瘤显示出变“热”的迹象。在GOBLET队列1中，接受pelareorep方案治疗四周后出现早期免疫激活的胰腺癌患者，其疾病无进展生存期比未出现激活的患者更长，分别为7.5个月和5.6个月。That same treatment combination previously posted a 62% objective response rate in first-line pancreatic cancer patients, more than double what chemotherapy alone has historically produced.. 同样的治疗组合之前在一线胰腺癌患者中达到了62%的客观缓解率，是历史上单独化疗所产生效果的两倍多。The data matter because they help explain the results 数据很重要，因为它们有助于解释结果。Oncolytics 溶瘤病毒学has already reported in colorectal cancer, where the backdrop is equally encouraging. The company 已经在结直肠癌中报道过，其背景同样令人鼓舞。公司recently launched 最近推出REO 033, a randomized Phase 2 trial testing pelareorep alongside bevacizumab and FOLFIRI in second-line RAS-mutated, microsatellite-stable metastatic colorectal cancer, a patient group with very few good treatment options today. REO 033是一项随机的二期试验，测试了在二线RAS突变、微卫星稳定型转移性结直肠癌中，将pelareorep与贝伐单抗和FOLFIRI联合使用的疗效，这一患者群体目前几乎没有良好的治疗选择。The trial builds on earlier results from REO 022, where the 该试验基于 REO 022 早期结果，其中same drug combination 相同药物组合produced 27 months of overall survival, 11.2 months of progression-free survival, and a 33% objective response rate, against 16.6 months, 5.7 months, and roughly 10% for the standard of care. The 产生了27个月的总生存期，11.2个月的无进展生存期，以及33%的客观缓解率，而标准治疗方案对应的数字分别为16.6个月、5.7个月和大约10%。FDA 食品药品监督管理局took notice, granting the regimen 注意到，并授予该制度Fast Track Designation 快速通道指定earlier this year. The second-line KRAS-mutant colorectal cancer market is estimated at $3 to $5 billion annually. REO 033 expects to open its first site next month, with preliminary data targeted for year-end 2026. 今年早些时候。第二线KRAS突变结直肠癌市场估计每年达30至50亿美元。REO 033预计下个月开设其首个站点，初步数据预计在2026年底发布。Oncolytics 溶瘤病毒学is a clinical-stage biotechnology company that has spent years building a scientific case for pelareorep across multiple tumor types. Across anal cancer, pancreatic cancer, and now colorectal cancer, the drug is accumulating a consistent body of evidence as something that may make other gastrointestinal cancer treatments work better. 是一家临床阶段的生物技术公司，多年来一直在为 pelareorep 在多种肿瘤类型中建立科学依据。在肛门癌、胰腺癌，以及现在的结直肠癌中，该药物正积累出一致的证据，表明它可能使其他胃肠道癌症治疗更有效。That kind of backbone role, if confirmed in larger trials, could position . 这种骨干作用，如果在更大规模的试验中得到证实，可能会定位为。Oncolytics 溶瘤学as a meaningful partner in the broader immuno-oncology landscape, where combination strategies are increasingly where the field is heading. 作为更广泛的免疫肿瘤学领域中有意义的合作伙伴，联合策略日益成为该领域的发展方向。CONTINUED… Read this and more news for Oncolytics Biotech at: 持续更新…请在此处阅读更多关于Oncolytics Biotech的新闻： https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ https://usanewsgroup.com/2024/09/21/溶瘤生物技术是市场最被低估的癌症机会吗/In other industry developments: 在其他行业发展中：Gilead Sciences 吉利德科学公司(NASDAQ: （纳斯达克：GILD 吉利德科学公司) )reported fourth quarter and full year 2025 financial results 报告了2025年第四季度和全年的财务结果showing oncology revenues of $3.2 billion for the year, anchored by a 6% increase in Trodelvy sales to $1.4 billion on higher breast cancer demand, while Yescarta received a label update removing a limitation around Primary Central Nervous System Lymphoma, making it the only CAR-T therapy in relapsed or refractory large B-cell lymphoma to have that restriction lifted. 显示全年肿瘤学收入为32亿美元，其中Trodelvy的销售额因乳腺癌需求增加而增长6%，达到14亿美元，同时Yescarta获得标签更新，取消了关于原发性中枢神经系统淋巴瘤的限制，成为唯一一款在复发或难治性大B细胞淋巴瘤中解除该限制的CAR-T疗法。The company also presented positive pivotal Phase 2 iMMagine-1 data for its Arcellx-partnered CAR T-cell therapy anitocabtagene autoleucel in 4L+ relapsed or refractory multiple myeloma at the 2025 American Society of Hematology meeting, with two additional cancer therapy launches anticipated in 2026.. 公司在2025年美国血液学会会议上公布了其与Arcellx合作的CAR T细胞疗法anitocabtagene autoleucel在四线及以上复发或难治性多发性骨髓瘤中的关键性二期iMMagine-1试验的积极数据，并预计在2026年推出另外两种癌症疗法。'In 2026, our potential new launches include two cancer therapies and an additional HIV treatment option, and we look forward to building on the launches of Yeztugo and Livdelzi for liver disease,' said Daniel O'Day, Chairman and CEO of “到 2026 年，我们潜在的新产品发布包括两种癌症疗法和一种额外的 HIV 治疗选择，我们期待在 Yeztugo 和 Livdelzi 治疗肝病的发布基础上再接再厉，”董事长兼首席执行官 Daniel O'Day 表示。Gilead Sciences 吉利德科学公司. 。Gilead Sciences 吉利德科学公司closed 2025 with $10.6 billion in cash and marketable debt securities and generated $10.0 billion in operating cash flow for the full year. For 2026, 截至2025年，持有106亿美元的现金和可售债务证券，并在全年产生了100亿美元的经营现金流。对于2026年，Gilead Sciences 吉利德科学公司guides for total product sales of $29.6 billion to $30.0 billion and non-GAAP diluted EPS of $8.45 to $8.85, with anticipated oncology launches expected to contribute meaningfully to growth alongside continued HIV franchise momentum. 预计总产品销售额将达到296亿美元至300亿美元，非公认会计准则下稀释每股收益为8.45美元至8.85美元，预期的肿瘤学产品上市将对增长做出重要贡献，同时HIV特许经营业务继续保持强劲势头。enGene Holdings 恩基控股(NASDAQ: （纳斯达克：ENGN 工程学) )reported Q1 2026 financial results 报告了2026年第一季度的财务结果reflecting continued advancement of its lead non-viral gene therapy candidate, detalimogene voraplasmid, toward a Biologics License Application submission targeted for the second half of 2026. The company's pivotal LEGEND cohort of 125 BCG-unresponsive NMIBC patients demonstrated a 63% complete response rate at any time and a 62% CR rate at 6 months, while . 反映了其主要的非病毒基因治疗候选药物detalimogene voraplasmid在2026年下半年提交生物制品许可申请（BLA）方面的持续进展。该公司的关键LEGEND队列研究纳入了125名对BCG无反应的非肌肉浸润性膀胱癌（NMIBC）患者，结果显示在任意时间点的完全缓解率为63%，6个月时的完全缓解率为62%。enGene Holdings 恩基控股closed Q1 with $312.5 million in cash and marketable securities. 第一季度末持有3.125亿美元的现金和可出售证券。'As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference,' said Ron Cooper, President and CEO of “随着LEGEND在高风险、BCG无反应的NMIBC关键队列的数据不断成熟，我们期待在春季医学会议上提供更新，”Ron Cooper表示，他是该公司的总裁兼首席执行官。enGene Holdings 恩基控股. 'With RMAT and CDRP designations for detalimogene, we are in active dialogue with the “随着detalimogene获得RMAT和CDRP称号，我们正在积极与FDA 食品药品监督管理局to ensure regulatory and manufacturing readiness as we plan for a BLA submission in the second half of this year and potential launch in 2027.' 为了确保在我们计划今年下半年提交BLA申请以及2027年潜在上市时，监管和生产方面准备就绪。enGene Holdings 恩基控股expanded its Hercules Capital debt facility to $125 million in January 2026, providing additional non-dilutive capital ahead of its planned commercial launch. The company expects its current cash position to fund operations into the second half of 2028, and 12-month complete response data from the LEGEND pivotal cohort is expected in 2H 2026.. 2026年1月，其赫拉克勒斯资本债务融资额度扩大至1.25亿美元，为公司计划的商业发布提供了额外的非稀释性资本。公司预计目前的现金储备将支持运营至2028年下半年，而LEGEND关键队列的12个月完全缓解数据预计将在2026年下半年公布。TScan Therapeutics TScan治疗公司(NASDAQ: （纳斯达克：TCRX TCRX) )reported Q4 and full year 2025 financial results 报告了2025年第四季度和全年的财务结果while providing updates on its TCR-engineered T cell hematologic malignancies program, including the completion of enrollment in Cohort C of the Phase 1 ALLOHA trial and 在提供其TCR工程T细胞血液恶性肿瘤项目的更新时，包括完成第一阶段ALLOHA试验C组的入组工作，以及FDA 食品药品监督管理局clearance of INDs for two new CD45-targeting candidates, TSC-102-A01 and TSC-102-A03. Full year 2025 collaboration and license revenue reached $10.3 million versus $2.8 million in 2024, with cash and equivalents of $152.4 million expected to fund operations into 2H 2027. 两款新的靶向CD45的候选药物TSC-102-A01和TSC-102-A03的IND申请已获批准。2025年全年合作与许可收入达到1,030万美元，而2024年为280万美元；预计现金及等价物1.524亿美元将支持公司运营至2027年下半年。'The regulatory and operational progress we have made over the last several months related to our heme program is exciting,' said Gavin MacBeath, Ph.D., CEO of “在过去的几个月里，我们在血液项目方面取得的监管和运营进展令人兴奋，”Gavin MacBeath博士说道。TScan Therapeutics TScan治疗公司. 'We expect the momentum to continue into the second quarter when we plan to share the initial data from patients enrolled into Cohort C in the ALLOHA study as well as initiate TScan's first Phase 3 trial. The data we presented at ASH in December 2025 continue to support our decision to focus the Company's efforts on development of therapeutics for patients with heme malignancies. “我们预计这种势头将持续到第二季度，届时我们计划分享来自ALLOHA研究中C队列患者的初步数据，并启动TScan的首个三期试验。我们在2025年12月的ASH上展示的数据继续支持公司将精力集中在为患有血液恶性肿瘤的患者开发治疗药物上的决定。”Additionally, the recent FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 will allow us to bring our TCR-T therapies to twice as many patients who currently have limited options in the post-transplant setting.'. 此外，TSC-102-A01 和 TSC-102-A03 的 IND 最近获得 FDA 批准，这将使我们能够将 TCR-T 疗法带给两倍数量的目前在移植后选择有限的患者。TScan Therapeutics TScan治疗公司discontinued its PLEXI-T solid tumor trial in November 2025 to concentrate resources on hematologic malignancies, and anticipates sharing preclinical proof-of-concept data from its autoimmunity program in 2H 2026. Updated Cohort C data and initiation of a Phase 1 study for TSC-102-A01 and TSC-102-A03 are both expected in the second half of 2026.. 于2025年11月停止了其PLEXI-T实体瘤试验，以集中资源于血液系统恶性肿瘤，并预计在2026年下半年分享其自身免疫项目临床前概念验证数据。更新的C组数据以及TSC-102-A01和TSC-102-A03的1期研究启动都预计在2026年下半年。Day One Biopharmaceuticals 第一天生物制药公司(NASDAQ: （纳斯达克：DAWN 黎明) )announced a definitive acquisition agreement 宣布了一项最终的收购协议under which 在...之下Servier 施维雅will acquire all outstanding shares of 将收购所有已发行的股份Day One Biopharmaceuticals 第一天生物制药公司for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The offer price represents a premium of approximately 68% over 每股 21.50 美元现金，总股权价值约为 25 亿美元。该报价较之前溢价约 68%。Day One Biopharmaceuticals 第一天生物制药公司' closing price on March 5, 2026, and approximately 86% over its one-month volume weighted average price, reflecting significant value recognition for the company's lead pediatric low-grade glioma program and broader oncology pipeline. 2026年3月5日的收盘价，较其一个月成交量加权平均价格高出约86%，反映出市场对公司领先的儿童低级别胶质瘤项目及更广泛的肿瘤学管线的重要价值认可。' 'Servier's 施维雅的successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of 在罕见癌症方面的成功记录及其对推进靶向治疗的承诺，使其成为我们作为部分的投资组合的理想归宿。Day One Biopharmaceuticals 第一天生物制药公司' mission to bring medicines to patients of all ages with life threatening diseases,' said Jeremy Bender, Ph.D., CEO of “为患有危及生命的疾病的各年龄段患者带来药物的使命，”杰里米·本德博士说道，他是该公司的首席执行官。Day One Biopharmaceuticals 第一天生物制药公司. 'Joining . ‘加入Servier 施维雅represents a unique opportunity to extend the reach of our science and our lead program in pediatric low-grade glioma.' 代表了一个独特的机会，可以扩大我们在小儿低级别胶质瘤方面的科学影响力和主导计划的覆盖范围。The transaction is subject to customary closing conditions, including shareholder tender and U.S. antitrust clearance, and is expected to close in Q2 2026. 该交易受制于常规的交割条件，包括股东要约和美国反垄断审查，并预计将于2026年第二季度完成。Day One Biopharmaceuticals 第一天生物制药公司' Board of Directors has unanimously recommended that shareholders tender their shares, and 董事会一致建议股东出让其股份，并且Servier 施维雅expects to fund the acquisition through existing cash and investments. 预计将通过现有的现金和投资为收购提供资金。Article Source: 文章来源： usanewsgroup.com usanewsgroup.comCONTACT: 联系人：USA NEWS GROUP 美国新闻集团[email protected] 电子邮件地址(604) 265-2873 (604) 265-2873DISCLAIMER: 免责声明：Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. 本出版物中的任何内容均不应被视为个性化的财务建议。我们并未根据证券法获得处理您特定财务状况的许可。我们员工与您的任何沟通都不应被视为个性化的财务建议。在做出任何投资决定之前，请咨询持牌财务顾问。This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. 这是一则付费广告，既不是购买或出售任何证券的要约，也不是推荐。我们不持有任何投资许可证，因此既无资格也无授权提供投资建议。本报告或电子邮件中的内容并非针对任何个人的具体情况提供。USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. 美国新闻集团是市场IQ媒体集团（MIQ）的全资子公司。MIQ已从Oncolytics Biotech Inc.直接获得广告和数字媒体费用。可能有第三方持有Oncolytics Biotech Inc.的股份，并可能抛售其股票，这可能会对股价产生负面影响。This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. 这种补偿构成了我们在与所介绍公司相关的沟通中保持客观能力的利益冲突。由于这一冲突，强烈建议个人不要将本出版物作为任何投资决策的依据。MIQ 的所有者/运营者拥有 Oncolytics Biotech Inc. 的股份。which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including th. 这些交易是在公开市场上进行的，并保留在任何时候买卖Oncolytics Biotech Inc.股票的权利，且不会另行通知，立即生效并持续进行。我们还预计会有进一步的补偿，作为一项持续的数字媒体工作，以提高公司的知名度，不再另行通知，但请以此免责声明作为通知，所有材料包括。SOURCES: 来源：https://www.pharmiweb.com/press-release/2026-02-19/oncology-market-value-to-more-than-double-reaching-usd-74817-billion-by-2035 https://www.pharmiweb.com/press-release/2026-02-19/肿瘤学市场价值将翻倍以上，到2035年达到74817亿美元https://www.openpr.com/news/4395526/immuno-oncology-market-set-for-remarkable-expansion-as https://www.openpr.com/news/4395526/免疫肿瘤市场将迎来显著扩张https://www.foley.com/insights/publications/2025/09/patent-cliff-ma-activity-for-companies-right-now/ https://www.foley.com/insights/publications/2025/09/patent-cliff-ma-activity-for-companies-right-now/https://www.pharmexec.com/view/fda-s-new-accelerated-approval-draft-guidance https://www.pharmexec.com/view/fda-s-new-accelerated-approval-draft-guidanceLogo - 标志 -https://mma.prnewswire.com/media/2838876/5873016/USA_News_Group_Logo.jpg https://mma.prnewswire.com/media/2838876/5873016/USA_News_Group_Logo.jpg21 21% %more press release views with 更多新闻发布视图与 Request a Demo 请求演示